Clinical trial
Phase 1B Study of PTC299 in Relapsed/Refractory Acute Leukemias
NCT03761069 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1B Study of PTC299 in Relapsed/Refractory Acute Leukemias
- Lead sponsor
- PTC Therapeutics
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- October 29, 2018
- Completion date
- December 28, 2021
- Enrollment
- 33 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.